PRIDE Complex: Papulopustules, Paronychia, Hair Growth Abnormalities, Itching, and Dryness Due to EGFR Inhibitors

A 51-year-old woman with metastatic colonic adenocarcinoma on cetuximab, an EGFR inhibitor, developed PRIDE complex, characterized by papulopustules, paronychia, hair growth abnormalities, itching, and dryness. These side effects are common with EGFR inhibitors, with papulopustular rash occurring in 56%-74% of patients. The rash and xerosis typically appear within 1-3 weeks of treatment, while paronychia and hair changes occur around 2-4 months. The papulopustular eruption may indicate a positive response to EGFR therapy. PRIDE complex does not necessitate stopping the EGFR inhibitor and can be managed with topical treatments and antihistamines.